InDex Pharmaceuticals updates shareholders list News provided by Share this article STOCKHOLM, March 12, 2021 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021. The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were as of February 26, 2021:
Publication The information was submitted for publication through the agency of the contact person set out above at 13:45 CET on March 12, 2021. InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.